#1 Clinical Trials Search in Europe

Baloxavir Marboxil

This article explores the use of Baloxavir Marboxil, also known as Xofluza, in clinical trials for the treatment of influenza. These studies aim to assess the drug’s effectiveness, safety profile, and potential benefits in various patient populations, including children, adults, and hospitalized individuals. The trials also investigate Baloxavir Marboxil’s role in reducing viral transmission and its comparison to other antiviral treatments.

Table of Contents

What is Baloxavir Marboxil?

Baloxavir Marboxil, also known by its brand name Xofluza, is an antiviral medication used to treat influenza (flu) infections[1]. It is a relatively new drug that works differently from older flu medications, offering a new approach to fighting the influenza virus[2].

How Does Baloxavir Marboxil Work?

Baloxavir Marboxil works by inhibiting an enzyme called polymerase acidic (PA) protein, which is essential for the influenza virus to replicate (make copies of itself) in the body[3]. By blocking this enzyme, Baloxavir Marboxil can stop the virus from spreading and multiplying, helping to reduce the severity and duration of flu symptoms[1].

What Conditions Does Baloxavir Marboxil Treat?

Baloxavir Marboxil is primarily used to treat influenza A and B infections in otherwise healthy individuals. It has been studied and approved for use in various scenarios:

  • Uncomplicated influenza: For patients aged 12 years and older who have been experiencing flu symptoms for less than 48 hours[1].
  • Pediatric patients: Studies have been conducted on children as young as 1 year old with influenza-like symptoms[1].
  • Severe influenza: Research is ongoing to evaluate its effectiveness in hospitalized patients with severe flu[2].
  • Post-exposure prevention: Studies are investigating its use in preventing flu transmission within households[4].

How is Baloxavir Marboxil Administered?

One of the key advantages of Baloxavir Marboxil is its simple dosing regimen:

  • Single-dose treatment: For most patients, Baloxavir Marboxil is given as a single oral dose, which is different from older flu medications that require multiple doses over several days[1].
  • Weight-based dosing: The dose is determined based on the patient’s weight. For example:
    • For patients weighing less than 80 kg (176 lbs): 40 mg
    • For patients weighing 80 kg (176 lbs) or more: 80 mg[5]
  • Formulations: It is available as tablets for older children and adults, and as an oral suspension for younger children[1].

Effectiveness of Baloxavir Marboxil

Clinical trials have shown that Baloxavir Marboxil can be effective in treating influenza when taken early in the course of the illness. Some key findings include:

  • Reduced duration of symptoms: Baloxavir Marboxil has been shown to shorten the time to alleviation of flu symptoms compared to placebo[1].
  • Faster viral clearance: Studies have demonstrated that the medication can reduce the amount of virus in the body more quickly than other treatments[1].
  • Potential for reducing transmission: Ongoing research is investigating whether Baloxavir Marboxil can help prevent the spread of flu within households[4].

Safety Profile and Side Effects

Baloxavir Marboxil has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects in some people. Common side effects may include:

  • Diarrhea
  • Bronchitis
  • Nausea
  • Sinusitis (inflammation of the sinuses)
  • Headache[1]

Serious side effects are rare but can occur. Patients should always discuss potential risks and benefits with their healthcare provider[2].

Use in Special Populations

Research is ongoing to understand the safety and effectiveness of Baloxavir Marboxil in various patient groups:

  • Pediatric patients: Studies have been conducted in children as young as 1 year old, with ongoing research in infants under 1 year[3].
  • Hospitalized patients: Investigations are underway to evaluate its use in combination with standard-of-care treatments for severe influenza requiring hospitalization[2].
  • Immunocompromised patients: Research is being conducted to assess its effectiveness in transplant recipients and other vulnerable populations[6].

Ongoing Research and Future Directions

Baloxavir Marboxil continues to be the subject of numerous clinical trials aimed at expanding its use and understanding its full potential. Some areas of ongoing research include:

  • Combination therapy: Studies are exploring the use of Baloxavir Marboxil in combination with other antiviral medications for severe influenza[2].
  • Post-exposure prophylaxis: Researchers are investigating whether the drug can prevent flu infections in people who have been exposed to the virus[4].
  • Early detection and treatment: Some studies are looking at using wearable devices to detect early signs of flu infection, allowing for prompt treatment with Baloxavir Marboxil[6].
  • Community-based interventions: Research is being conducted on using Baloxavir Marboxil as part of “test-and-treat” strategies in vulnerable communities[7].

As research continues, our understanding of Baloxavir Marboxil’s role in treating and preventing influenza is likely to evolve, potentially leading to new applications and treatment strategies in the future.

Aspect Details
Study Types Phase I, II, III, and IIIb clinical trials
Patient Populations Children (from birth to <12 years), adults, hospitalized patients, healthy volunteers
Primary Objectives Assess efficacy, safety, pharmacokinetics, and tolerability of Baloxavir Marboxil
Secondary Objectives Evaluate viral transmission reduction, compare to other antivirals, assess impact on hospitalization duration
Dosing Single oral dose, weight-based (e.g., 40 mg for <80 kg, 80 mg for ≥80 kg)
Key Outcome Measures Time to symptom alleviation, viral load reduction, adverse events, transmission rates
Study Designs Randomized, placebo-controlled, open-label, single-arm
Special Focus Areas Household transmission, pediatric patients, hospitalized patients, early detection and treatment

FAQ

  • What is Baloxavir Marboxil? Baloxavir Marboxil, also known by the brand name Xofluza, is an antiviral medication used to treat influenza (flu). It works by inhibiting the influenza virus from replicating in the body.
  • How is Baloxavir Marboxil administered? Baloxavir Marboxil is typically administered as a single oral dose, with the dosage based on the patient's weight. It can be given as tablets or as an oral suspension for younger patients or those who have difficulty swallowing pills.
  • What are the main goals of the clinical trials involving Baloxavir Marboxil? The clinical trials aim to evaluate the efficacy and safety of Baloxavir Marboxil in treating influenza, assess its ability to reduce viral transmission, compare it to other antiviral treatments, and determine its effectiveness in various patient populations, including children and hospitalized individuals.
  • Are there any potential side effects of Baloxavir Marboxil? While specific side effects are not detailed in the provided trial information, the studies are monitoring for adverse events and serious adverse events. As with any medication, there may be potential side effects, which are being carefully evaluated in these clinical trials.
  • How might Baloxavir Marboxil benefit patients with influenza? Baloxavir Marboxil may help reduce the duration of flu symptoms, shorten the time to clinical improvement, decrease viral shedding, and potentially reduce the risk of complications associated with influenza. Some trials are also investigating its ability to prevent transmission of the virus to household contacts.

Ongoing Clinical Trials on Baloxavir Marboxil

  • Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Estonia France Italy The Netherlands Portugal +3

  • Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +7

  • Study on Baloxavir Marboxil for Children with Influenza

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Poland Spain

Glossary

  • Baloxavir Marboxil: An antiviral medication used to treat influenza, also known by the brand name Xofluza. It works by inhibiting the replication of the influenza virus in the body.
  • Influenza: A contagious respiratory illness caused by influenza viruses that can cause mild to severe illness, commonly known as the flu.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, often used to evaluate new treatments, drugs, or devices.
  • Placebo: A substance that has no therapeutic effect, used as a control in testing new drugs. In these trials, it's often referred to as a 'mock treatment'.
  • Efficacy: The ability of a treatment to produce a desired effect under ideal conditions, such as in a clinical trial.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or is otherwise medically significant.
  • Viral Shedding: The release of virus from an infected individual, usually through respiratory secretions, which can potentially infect others.
  • Polymerase Chain Reaction (PCR): A laboratory technique used to amplify small segments of DNA or RNA, often used to detect the presence of viral genetic material.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Antiviral: A type of medication used to treat viral infections by inhibiting the development of the virus.
  • Oseltamivir: Another antiviral medication used to treat and prevent influenza, often known by the brand name Tamiflu.
  • Household Contact (HHC): A person living in the same household as someone infected with a contagious disease, who may be at risk of contracting the infection.
  • Index Patient (IP): The first identified case of a disease in a group of related cases, often used in studies of disease transmission within households.
  • Titer: A measurement of the amount or concentration of a substance in a solution, often used to quantify the amount of virus in a sample.

References

  1. https://clinicaltrials.gov/study/NCT03629184
  2. https://clinicaltrials.gov/study/NCT03684044
  3. https://clinicaltrials.gov/study/NCT03653364
  4. https://clinicaltrials.gov/study/NCT03969212
  5. https://clinicaltrials.gov/study/NCT03959332
  6. https://clinicaltrials.gov/study/NCT06161454
  7. https://clinicaltrials.gov/study/NCT06207058